InMed Pharmaceuticals (CAN:IN / US:IMLFF) has become the first company to conduct human clinical trials involving the rare cannabinoid, cannabinol (CBN). InMed is using cannabinol as the active ingredient in two cannabis-based drug product candidates.
On January 20, 2020; InMed announced that INM-755 (for epidermolysis bullosa) and INM-088 (for glaucoma) both feature CBN as the active ingredient. CEO Eric Adams framed this for investors.
We are simultaneously exploring innovative biosynthetic manufacturing methods and therapeutic applications of CBN formulations to target diseases with high unmet medical need.”
The cannabis plant contains roughly 100 known cannabinoids. However, most of these cannabinoids are only found in trace amounts. This has made studying the therapeutic potential of these rare cannabinoids nearly impossible using conventional scientific means.
InMed has proprietary technology that allows the company to isolate and study these rare cannabinoids. It is also pioneering a means for synthesizing these rare cannabinoids so that they can become practical for commercial applications.
INM-755 is InMed’s lead dermatological product for the treatment of epidermolysis bullosa (EB). EB is a rare genetic skin disease that can lead to extensive wounds and blistering.
INM-755, a topical cream, is being tested to treat the inflammation and pain that accompanies EB. InMed also believes that INM-755 has the potential to “enhance skin integrity” for some EB patients.
Shares in InMed jumped ovber 50% on the news to CAD$0.375. The stock is currently trading at CAD$0.32.
With medicinal cannabis already being widely prescribed for the treatment of hundreds of medical conditions, The Seed Investor sees enormous potential for cannabis biopharma.
The global pharmaceutical industry represents roughly a $1 trillion per year revenue pie. But many of the drugs currently in commercial use carry high user risks of serious (sometimes life-threatening) side effects.
Cannabinoids are produced naturally in the human body. For this reason, cannabinoid-based drugs exhibit a remarkably benign safety/tolerance profile. This makes cannabinoid-based drugs eligible for fast-tracking through the clinical trials process.
As InMed (and other cannabis companies) advance cannabinoid-based drugs through the clinical trials process, cannabis investors will want to keep an eye out for opportunities on this front.
DISCLOSURE: The writer holds shares in InMed Pharmaceuticals.
Published at Wed, 22 Jan 2020 18:12:59 +0000